65 results about "Chronic pain" patented technology

Systems and methods for providing recommended doses and instructions for pharmaceutical treatments, and more particularly systems and methods for measuring physiological and / or electrophysiological signals from a subject and providing recommended doses and instructions of pharmaceuticals based at least in part on the measured signals are described. Further, the recommended doses and instructions are based at least in part on a subject's disease(s), disorder(s), or injuries and / or symptom(s) of such, and / or side effects of medications or treatments the subject is receiving. The recommended doses and instructions are personally tailored to the subject to precisely and personally address the subject's needs, and may be based in part on correlation with database(s) comprising historical data of the subject and / or other subjects to treat the subject's movement disorders, injuries to the body or brain, cognitive diseases and disorders, sleep diseases and disorders, chronic pain, or other conditions.

The invention discloses an exercise management method and system for musculoskeletal chronic pain, and relates to the technical field of exercise management rehabilitation, and the method comprises the steps: building a biomechanical model for a patient through finite element analysis software, determining an optimal exercise mode according to the pain mode and the activity ability of the patient, and generating an exercise track through a path planning algorithm, on the basis of micro-current collaborative feedback data, the pain change trend of the patient is calculated, and a motion adjustment plan is generated, a biomechanical model can truly reflect the force distribution conditions of the patient under different motions, the safety of a motion scheme is remarkably improved, and the potential injury risk is reduced; scientific basis is provided for dynamically adjusting the exercise intensity, the obtained exercise adjusting plan can respond to the state change of the patient in time, and the intelligent level and the long-term curative effect of rehabilitation management are further enhanced.

The invention discloses a system for treating chronic lumbago through the synergistic effect of massage and whole body vibration training. The system comprises a patient information registration and management module, a chronic pain evaluation module, a treatment effect evaluation module, a data analysis and feedback module, a vibration training control terminal and a massage treatment and guidance module. A patient is guided to complete standardized waist actions, pain scores under various postures are recorded, a main pain area is determined in combination with a Pareto analysis method, an average value and standard deviation model is constructed by using score data in multiple treatments, and normal distribution fitting and curative effect judgment of pain changes are further achieved. Massage and vibration training are linked through the system, data intercommunication is achieved, standardized, intelligent and personalized intervention in the treatment process is achieved, and the rehabilitation efficiency of the chronic lumbago patient is effectively improved. The system has the advantages of complete structure, scientific evaluation, accurate intervention and the like, and is suitable for popularization and application in the fields of rehabilitation medicine and clinical physical treatment.

The present invention is directed to novel compounds that inhibit Nav1.8 sodium channels, methods of making, and methods of using thereof. The present disclosure is further directed to administering the disclosed compounds as therapeutic solutions for chronic pain, primary pain, idiopathic pain, gastrointestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer-related pain, idiopathic pain, postoperative pain, visceral pain, multiple sclerosis, Summer-Marr-Tuff syndrome, incontinence, pathological cough, or arrhythmia to a subject in need thereof.

The invention provides an intelligent relieving system and method for phantom pain after breast resection based on biofeedback, develops a non-drug and non-invasive intelligent system, recognizes the phantom pain state in real time through multi-dimensional biofeedback, dynamically adjusts an intervention strategy, and solves the problems of high dependency and poor universality of a traditional method. Specifically, through multi-modal signal fusion, sEMG (surface electromyography), heart rate variability (HRV) and skin conductance (EDA) data are integrated, and the accuracy of magic pain recognition is improved. Through an adaptive algorithm, feedback parameters (such as electrical stimulation intensity and virtual reality scenes) are dynamically optimized based on an AI analgesia intervention model (such as LSTM), and personalized intervention is realized. According to the invention, a dynamic adjustment mechanism is integrated for magic pain for the first time, and the limitation of a traditional single intervention mode is broken through based on a self-adaptive adjustment strategy of a multi-modal signal. The occurrence rate of postoperative chronic pain is reduced, and consumption of medical resources is reduced. An intelligent tool is provided for nursing science, and the development of'precise nursing 'is promoted.

A method of producing a population of mature human pluripotent stem cell-derived sensory neurons (hPSC-SNs) expressing a target gene associated with at least one of nociceptive pain, chronic pain, pruriception and a nociceptive- or pruriceptive- mediated condition, the method comprising introducing into a population of human pluripotent stem cells (hPSCs) a composition comprising at least one site-directed nuclease targeting a site within the target gene, and at least one nucleic acid comprising a nucleotide sequence encoding at least one screenable, selectable marker that is flanked by (i) a nucleotide sequence homologous with a region located upstream of the target site within the target gene and (ii) a nucleotide sequence homologous with a region located downstream of the target site within the target gene, wherein the target site is located downstream of the open reading frame of the target gene, and wherein the site-directed nuclease cleaves the target site of the target gene and the nucleic acid encoding the screenable, selectable marker is inserted at the target site; covering said population of hPSCs under an extracellular matrix comprising at least one neuronal differentiation driver to produce a sensory committed neural crest population; contacting said sensory committed neural crest population with at least one neuronal differentiation driver and at least one neurotrophic factor to produce a population of early sensory neurons (SNs); and contacting said population of early SNs with at least one neurotrophic factor to produce a population of mature hPSC-SNs expressing at least one of SN marker or one pan neuronal marker; isolating the cells expressing the at least one screenable, selectable marker, wherein said population of mature hPSC-SNs expressed said one target gene associated with nociceptive pain, chronic pain, pruriception a nociceptive- or pruriceptive- mediated condition, and wherein said population of mature hPSC-SNs responds to a nociceptive and pruriceptive stimulus.

The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.

The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. 5 The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration. 20 26 21 41 00 10 A ug 2 02 6 1 0 A u g 2 0 2 6 2 0 2 6 2 1 4 1 0 0

Provided herein are methods of nerve blockage, for example for treatment of obesity, heart failure, cardiovascular disease, muscle spasms, chronic pain, or urinary retention in a patient. The method comprises first heating a nerve above physiological temperature (e.g., 37° C. in a human), such as from 43° C. to 54° C. for a duration that leads to reversible nerve blockage as opposed to nerve damage. Second, reversible nerve blockage is produced by cooling the nerve below physiological temperature to a temperature in which reversible nerve blockage is achieved, for example from 15° C. to 30° C.

This invention provides a class of multi-target heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF. These heteropeptides use the small-molecule N-4-piperidinyl-N-phenylpropionamide and the polypeptide-structured neuropeptide FF as chemical templates. A series of peptide-small-molecule hybrid peptides are obtained by chemically coupling the pharmacophores of the N-4-piperidinyl-N-phenylpropionamide analog and the neuropeptide FF. In vivo pharmacological activity identification in animals shows that these heteropeptides possess analgesic activity without opioid-like side effects such as addiction and respiratory depression. Furthermore, compounds 1-4 and compounds 7-9 do not exhibit analgesic tolerance and can be used for long-term analgesic treatment of chronic pain. Therefore, these heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF can be used to prepare analgesic drugs.

The application provides an electroencephalogram pain positioning device, a training method and equipment, and constructs an electroencephalogram pain positioning device including a preprocessing module, a double-branch space-time coding backbone network, a mixed expert-weight decomposition low-rank adaptation module and a detection head. The double-branch space-time coding backbone network includes a coarse-grained branch for extracting low-frequency global features of electroencephalogram signals and a fine-grained branch for extracting high-frequency transient detail features of electroencephalogram signals. In this way, the transient high-frequency features of acute pain and the continuous low-frequency oscillation features of chronic pain can be captured at the same time, and the problem that a single scale network cannot consider the dynamic characteristics of different pain types is solved.

The described technology pertains to the field of orthopedic devices, specifically foot braces adapted for treating plantar fasciitis and other foot and ankle conditions. The technical problem addressed is the impracticality of traditional taping techniques for long-term use due to their rapid degradation and the need for specialized training. This technology provides a durable, user-friendly orthopedic device that mimics the mechanical support and forces of the low dye taping method. This device offers effective support and relief for foot and ankle ailments, enhancing mobility and reducing symptoms. The primary use of this technology is in sports medicine, rehabilitation, and orthopedics to aid recovery and provide pain relief. The device is constructed to adjust to individual anatomical differences, overcoming the limitations of existing one-size-fits-all solutions. The described technology is characterized by the ability to maintain supportive properties over extended periods, unlike traditional taping methods.

The invention discloses siRNA (small interfering ribonucleic acid) targeting SOX7, application of the siRNA in preparation of a medicine for treating chronic pain and the medicine, the small interfering RNA targeting the SOX7 gene comprises the SOX7 siRNA, the positive-sense strand sequence of the SOX7 siRNA is shown as SEQ.ID.NO.1, the antisense strand sequence of the SOX7 siRNA is shown as SEQ.ID.NO.2, and the small interfering RNA can target SOX7 genes of human and mice at the same time. The SOX7 siRNA is a group of siRNA for inhibiting the expression of the SOX7 gene, and siRNA targets are designed in a conserved region of the SOX7 gene and are located in a coding region. The expression of the SOX7 gene can be effectively reduced in vivo; by inhibiting the expression of the SOX7 gene, mechanical hyperalgesia generated by SNL induction can be effectively relieved, a foundation is laid for clinical treatment of sexual pain, and the application and popularization value is great.

The present invention relates to a sulfonylurea derivative and medical uses thereof, specifically relating to the sulfonylurea derivative shown in general formula (I), a preparation method thereof, a pharmaceutical composition containing same, and a use of same for treating diseases and disorders affected by neuronal damage, for example: cerebral stroke, brain damage, neuropathic pain, migraines, inflammatory pain, chronic pain, or depression. The definition of each group in the general formula (I) is the same as that in the description.

The invention relates to compounds, compositions, and methods for derepressing RE1 silencing transcription factor (REST) target genes are provided. In particular, a peptide having the sequence TEDLEPPEPPLPKEN (SEQ. ID NO: 1) and EDLEPPEPPLPK (SEQ. ID NO: 15), or the reversed sequences made of D-amino acids (retro inverted, RI) nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), are disclosed for inhibiting REST activity. The peptides are useful to treat, prevent, or ameliorate conditions such as traumatic brain injury, epilepsy, dementia, Huntington's Disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer; diabetes, and peripheral nerve injury

The invention provides a coal mining screening mechanism which is characterized in that a heating unit is arranged on the surface of the side, attached to a joint, of a bearing cover, a mounting shell is fixed to the surface of the other side of the bearing cover, a driving assembly for forming one-way airflow at the joint hot compress position is arranged in the mounting shell, and the driving assembly absorbs moisture of air passing through the interior of the driving assembly; the two driving exercise assemblies are symmetrically arranged, and the two driving exercise assemblies are arranged on the two sides of the bearing cover and connected to the upper mounting cover and the lower mounting cover; the knee joint bends and stretches to drive the upper mounting cover and the lower mounting cover to rotate relatively, the driving exercise assembly provides resistance, and therefore the weight-bearing exercise effect is achieved. By constructing the constant-temperature drying and heating cavity and combining resistance-resistant exercise, hot compress and exercise collaboration is achieved, and the comfort, functionality and chronic pain relieving effect of knee joints are improved.

The invention provides an electroencephalogram pain positioning device, a training method and equipment, and constructs the electroencephalogram pain positioning device comprising a preprocessing module, a double-branch space-time coding backbone network, a hybrid expert-weight decomposition low-rank adaptation module and a detection head. The double-branch space-time coding backbone network comprises a coarse-grained branch used for extracting low-frequency global features of the electroencephalogram signals and a fine-grained branch used for extracting high-frequency transient detail features of the electroencephalogram signals, so that transient high-frequency features of acute pain and continuous low-frequency oscillation features of chronic pain can be captured at the same time, and the accuracy of the transient high-frequency features of the acute pain and the continuous low-frequency oscillation features of the chronic pain can be improved. The problem that a single-scale network cannot give consideration to dynamic characteristics of different pain types is solved.

The application discloses a kind of massage and whole body vibration training synergistic effect treatment chronic low back pain system, including patient information registration and management module, chronic pain assessment module, treatment effect assessment module, data analysis and feedback module, vibration training control terminal and massage treatment and guidance module;Through guiding patient to complete standardization waist action and record each posture under the pain score, determine main pain area in combination with Pareto analysis method, and utilize the score data in multiple treatments, construct mean and standard deviation model, and then realize the normal distribution fitting of pain change and curative effect determination;Massage and vibration training are linked through system, data intercommunication, realize the standardization of treatment process, intelligent and personalized intervention, effectively improve the rehabilitation efficiency of chronic low back pain patient.The application has the advantages of complete structure, scientific evaluation, precise intervention, etc., and is suitable for the popularization and application in the field of rehabilitation medicine and clinical physical therapy.

The invention provides sinomenine in preparation of a medicine for treating chronic pain of rheumatoid arthritis and application of the sinomenine in preparation of the medicine for treating the chronic pain of the rheumatoid arthritis, and aims at solving the problems that an existing medicine for resisting the rheumatoid arthritis is limited in action target spot and poor in treatment effect. The sinomenine takes a histamine receptor H1R on a nervous system dorsal root ganglion M1 type macrophage as the action target spot; the target spot is intervened to regulate and control polarization of macrophages, reduce expression of histamine H1R in M1 type macrophages and inhibit infiltration of the macrophages, so that chronic pain, including crymodynia, mechanical pain, heat pain and the like, of rheumatoid arthritis is effectively relieved; the sinomenine combined action target can improve pain and arthritis symptoms of a model mouse, reduce the level of inflammatory factors and inhibit LPS-induced macrophage migration and H1R expression, and the sinomenine pharmaceutical composition has various dosage forms, has unique action target and mechanism, has a remarkable treatment effect, and can be used for preparing medicines for treating chronic infectious diseases. The compound is expected to become a novel non-opioid anti-rheumatoid arthritis chronic pain medicine.

This invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as their pharmaceutically acceptable compositions, methods of preparation, and uses. The MAGL small molecule inhibitors are represented by formula (I), having the specific substituents and definitions described herein. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. This invention includes these compounds or their pharmaceutically acceptable compositions for the treatment and / or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasticity.

A transcutaneous magnetic stimulation (tMS) device is provided for modulating nerve function and chronic pain management, and includes a tMS stimulator, a control module in wired and powered communication with the tMS stimulator, and a portable electronic device in wireless communication with the control module to receive, generate and transmit feedback and control settings relating to a treatment session. The tMS stimulator may be a flexible figure-of-eight coil configured in different sizes and shapes to provide varying pulse and magnetic field strengths for mobile, home, or clinical uses, and also include guidance tools and measurement sensors to aid in positioning and directing the tMS stimulator to a target area for treatment.

The present invention relates to epiregulin antibodies, compositions comprising the same, and methods of making and / or using the antibodies and / or compositions thereof for chronic pain disorders such as chronic osteoarthritis pain, or chronic diabetic peripheral neuropathy pain, or chronic low back pain.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for promoting menstruation and removing stasis, an external preparation and application. The traditional Chinese medicine composition consists of teasel root, lycopodium clavatum, frankincense, myrrh, divaricate saposhnikovia root, pseudo-ginseng, turmeric, cinnamon, litsea cubeba, ligusticum wallichii, gardenia, mulberry twig, lotus leaf, rheum officinale, dragon's blood, salvia miltiorrhiza, safflower, folium artemisiae argyi and mint. The traditional Chinese medicine composition for promoting menstruation and removing stasis is reasonable in compatibility, has an excellent treatment effect on wind-cold-dampness arthralgia, and is suitable for patients with symptoms such as scapulohumeral periarthritis, cervical spondylosis, lumbocrural pain, muscle and joint pain, rheumatic arthritis, rheumatoid arthritis and gouty arthritis. A specific natural penetrant composition and a traditional Chinese medicine composition are selected to be prepared into an external dosage form, the medicine can be promoted to enter a target organ or tissue through a physiological barrier, the medicine can directly act on a focus, the effect is quick, the efficacy is lasting, the use is convenient, the patient compliance is good, no toxic or side effect exists, and a new choice of an external transdermal agent is provided for clinical treatment of chronic pain.

The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.

The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and / or lymphoproliferation.

Provided herein are methods for blocking nerves, for example, for treating obesity, heart failure, cardiovascular disease, muscle spasms, chronic pain, or urinary retention in postoperative patients. The methods can include first heating the nerve to a temperature above physiological temperature (e.g., human body temperature of 37°C), for example, in the range of 43°C to 54°C, for a period of time, which results in reversible nerve blockade, which is the opposite of nerve damage. Second, reversible nerve blockade can be produced by cooling the nerve to a temperature below physiological temperature, where reversible nerve blockade can be achieved, for example, in the range of 15°C to 30°C.

The invention discloses a composition for relieving chronic pain related depressive mood. The composition is mainly prepared from the following traditional Chinese medicinal materials in parts by weight: 5-30 parts of borneol, 5-30 parts of musk, 50-100 parts of liquorice, 50-100 parts of burdock, 50-100 parts of gardenia kernel, 20-60 parts of calculus bovis, 50-100 parts of acorus gramineus and 50-100 parts of radix curcumae. Molecular mechanisms and potential treatment effects of borneol powder for treating chronic pain related depressive mood are researched by a modern scientific method, and safety and effectiveness of medicines are evaluated by pharmacodynamic and toxicological evaluation and animal experiments, so that the traditional Chinese medicine composition capable of effectively relieving chronic pain related depressive mood is provided.

A method for providing an application recommendation comprising sending a first survey to a user’s device, receiving usage statistics of a plurality of applications on the user’s device, receiving first result data of the survey and recommending an application based on the result data and usage statistics. An impact score for each application of the plurality of applications may be calculated which represents an impact each application has on the survey result data. An impact matrix based on the impact score may be built which represents an average impact of each application. The impact score and matrix may be sent to a data storage and the usage statistics and survey result data may be processed with the matrix to generate the recommendation. A wait period may be initiated in response to the first survey being completed, the first result data being sent to storage or in response to the user not opening the first survey. A second survey may be sent after the wait period ends and may be accessed through a URL sent to the user device. The recommendation may be made to improve the user’s mental health and wellbeing or chronic pain, for example.

The invention belongs to the technical field of oligopeptide pharmacology, and particularly discloses a Maged1 competitive oligopeptide and application thereof. The Maged1 competitive short peptide is a short peptide MP1 or a short peptide MP2, and the amino acid sequence of the Maged1 competitive short peptide is as shown in SEQ ID No. 1 or SEQ ID No. 2. Experiments prove that the Maged1 competitive oligopeptide and Maged1 can be competitively combined with a P2X3 receptor, so that activation of the Maged1 on the P2X3 receptor is inhibited, and the Maged1 competitive oligopeptide has a good clinical application prospect in treatment of chronic pain.